Why Shares of Eli Lilly Soared This Week
Shares in Eli Lilly (NYSE: LLY) had risen 13.2% in the week to Friday morning. The move comes at a time when peer announced a deal with the Trump administration that gave that pharmaceutical company three years of grace from tariffs imposed on drugs it manufactures abroad and imports to the U.S.. The deal, which is conditional on Pfizer investing in manufacturing in the U.S., raises hopes that Eli Lilly will also come to a similar agreement with the government.
Eli Lilly is in a good position for a couple of reasons. First, it's already investing heavily in the U.S. with a $5 billion manufacturing facility planned in Virginia, as well as a $6.5 billion manufacturing facility planned in Texas.
Second, Eli Lilly has already announced an intent to rebalance the costs of its research by increasing the prices paid by governments and healthcare bodies "in other developed markets like Europe in order to make them lower in the U.S."
Source Fool.com
Pfizer Inc. Aktie
Durchaus positiv bewertet unsere Community derzeit Pfizer Inc. mit 14 Buy-Einschätzungen und 2 Sell-Einschätzungen.
Bei einem Kursziel von 27 € ergibt sich ein positives Potenzial von 27.9% für Pfizer Inc. im Vergleich zum aktuellen Kurs von 21.11 €.
